–
Celltrion(355,000 +2.16%)Announced that CT-P59 (ingredient name regdanvimab), an antibody treatment for novel coronavirus infection (Corona 19) under development, also works on mutant viruses. The company plans to apply for conditional approval this week after it is ready to submit clinical results.
–
–
Woosung Ki CelltrionThe group’s vice chairman said at the ‘2020 Korea Bio-investment Conference (KBIC)’, which opened for two days at Dragon City, Hangang-ro, Seoul on the 28th.
At this event co-hosted by the Korea Bio Association and the Korea Economic Daily, Vice Chairman Gi said, “CT-P59 is expected to reduce the progression to severe patients by focusing on early treatment for mild patients.” It was confirmed that CT-P59 actually works for 19 viruses.”
CelltrionHas been analyzing safety and efficacy data after completing phase 2 clinical administration of CT-P59 last month. It is currently in the production stage of the treatment. CelltrionIn order to shorten the time until the actual prescription, it has produced an initial quantity of CT-P59 that can be treated by 100,000 people since last September.
Reporter Kim Ye-na [email protected]
–
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution
–
